Harbour BioMed Announces Phase I Results for HBM9378, A Novel TSLP-Targeting Antibody Harbour BioMed has released Phase I trial results for its antibody HBM9378, which targets TSLP and shows promise for treating immunological disorders.

Harbour BioMed Announces Phase I Results for HBM9378, A Novel TSLP-Targeting Antibody #China #Chengdu #HBM9378 #Harbour_BioMed #TSLP

Harbour BioMed's Groundbreaking Phase 2 Trial of HBM9378/WIN378 for Asthma Harbour BioMed has launched a global Phase 2 clinical trial for HBM9378/WIN378—a promising long-acting antibody aimed at asthma treatment, with key data expected by mid-2026.

Harbour BioMed's Groundbreaking Phase 2 Trial of HBM9378/WIN378 for Asthma #None #HBM9378 #Harbour_BioMed #Anti-TSLP

Harbour BioMed Partners with Windward Bio to Advance HBM9378/SKB378 for Immunological Disease Treatment Harbour BioMed and Windward Bio enter a license agreement for HBM9378, an innovative antibody aimed at treating immunological diseases, signaling promising medical advancements.

Harbour BioMed Partners with Windward Bio to Advance HBM9378/SKB378 for Immunological Disease Treatment #None #HBM9378 #Windward_Bio #Harbour_BioMed